AI-Augmented Clinical Trials & Drug Development Evolution in India

Jennifer Li, SVP & Head of APAC Sales, Medidata, engaged in a conversation with Thiruamuthan, Assistant Editor at India Pharma Outlook, discusses how AI is transforming clinical trials in India by accelerating patient recruitment, enhancing data analysis, and enabling predictive decision-making. She highlights leveraging genetic diversity, real-world data, evolving regulations, and ecosystem collaborations to drive inclusive, efficient, and scalable drug development.

Jennifer Li, a life sciences business leader, brings over 18 years of experience across clinical research and analytics. She specializes in business strategy, sales leadership, data analytics, and statistical modeling, with strong expertise in driving growth, market expansion, and commercial excellence.

AI is enhancing clinical trial efficiency, particularly in data analysis and patient recruitment. How has AI technology impacted these areas in India, and where is it most effective?

AI's most significant impact is in improving patient recruitment and participation, which is driven by its ability to efficiently handle large volumes of complex information.

As AI excels at processing massive amounts of data in seconds, a task that would take humans years, this capability can be leveraged to increase and improve patient recruitment through the three key pillars.

Advanced Screening and Targeting: AI mines complex sources like Real-World Data (RWD) and electronic health records (EHR) to identify qualified participants and detect patterns that manual analysis would miss. This capability enables more targeted outreach and significantly shortens recruitment timelines.

Predictive Site Performance: The technology also uses this complex information to predict which research sites are most likely to recruit effectively.

Handling Complexity: The efficient management of high levels of complexity is essential, particularly in areas like clinical trial imaging, where over 50 percent of trials and 95 percent of oncology trials rely on it.

At Medidata, we believe that embedding AI across the clinical trial lifecycle is key to driving meaningful transformation in drug development, having delivered tangible results, such as reducing study startup time by up to 75 percent and study build time by as much as 80 percent.

India’s genetic diversity impacts personalized medicine. How is AI leveraging this diversity to optimize patient recruitment and outcomes in clinical trials across the country?

India's genetic diversity creates a real opportunity for clinical research, however, it remains underutilized. With its diverse and treatment-naïve population, AI can change this to not just enable more inclusive trials but also increase the country's trial capacity and positioning as a global clinical trial hub. 

For example, AI can mine RWD across diverse geographic regions, including tier-2 and tier-3 cities where large patient populations exist but trial participation has been traditionally low. In doing so, it can identify qualified participants from a previously untapped pool whose genetic and demographic profiles match trial requirements to create a more representative patient cohort. Not only does this accelerate recruitment, but it also generates outcomes data that reflects India's actual patient population.

Also Read: Anti-Infectives: How New Research is Shaping Infection Control

India’s evolving regulatory environment for AI in healthcare presents challenges. What regulatory hurdles does AI-driven drug development face in India, and how are they being addressed?

An emerging challenge as clinical trials become more technology-enabled and AI-driven is aligning innovations within existing frameworks designed for traditional trials. However, India's regulatory environment is evolving and moving in the right direction to address these hurdles.

Earlier this year, the Union Ministry of Health and Family Welfare announced key amendments to the New Drugs and Clinical Trials Rules. The reforms aim to streamline approvals, reduce regulatory timelines, and establish clearer pathways for technology-enabled trials to accelerate clinical research and drug development in the country.

While streamlined approvals can fast-track access to new therapies, patient consent and data privacy remain critical. The way forward lies in regulators, sponsors, and technology providers co-creating intuitive, accessible systems that protect patient rights while upholding ethical standards and enabling innovation.

AI algorithms are reshaping clinical trial efficiency. What trends in predictive analytics or machine learning are most transforming trial designs and reducing timelines in India?

The first key transformation is patient recruitment and trial startup timelines. Machine learning algorithms analyze vast datasets to predict which patient populations are most likely to meet trial criteria and remain engaged, while simultaneously forecasting which research sites will perform best based on historical performance. By identifying high-potential patient groups and predicting site-level recruitment success, resource allocation can be enhanced, and recruitment and trial startup timelines can be reduced.

Beyond recruitment, AI is revolutionizing real-time risk detection and decision-making. Machine learning continuously monitors incoming trial data to flag inconsistencies, protocol deviations, and safety signals in real time. Additionally, it also analyzes historical data to anticipate treatment efficacy, dropout risks, and adverse events, enabling researchers to make proactive, risk-averse decisions.

We are also seeing the rise of digital twins and adaptive trial design. AI can create virtual patient models by integrating diverse data sources, allowing researchers to simulate disease progression and predict how different patient populations might respond to therapies. This enables teams to test and iterate study designs before implementing them in real-world settings.

Pharmaceutical companies in India are collaborating with startups to harness AI innovations. How are these collaborations structured, and what impact do they have on drug development processes?

The pharmaceutical industry is increasingly recognizing that accelerating drug development requires ecosystem collaboration – with startups, tech innovators, research institutions, regulators, and healthcare providers. Rather than siloed approaches, companies are building partnerships across the entire value chain. This collaborative ecosystem approach can compress timelines and reduce costs through shared infrastructure and data.

Also Read: Strategies for Transparency and Patient-Centered Care

Looking ahead, how do you foresee the role of AI evolving in clinical trials over the next 5-10 years, especially in terms of scalability and innovation?

Over the next 5-10 years, I foresee AI becoming part of the infrastructure for clinical research, much like electronic data capture did a decade ago. To see real transformation, this will be coupled with partnerships that bridge pharma, technology, and patient advocacy around interoperability and data sharing.

The biggest opportunity lies in connecting clinical, real-world, and patient-reported data in ways that are usable and secure. This will happen through the continued adoption of interoperability standards that create common language across systems, as well as disruption through emerging technologies like agent-to-agent communication that enable seamless data exchange.

When pharma teams up with platforms that can crack interoperability, we'll see faster drug development, more precise insights, and a seamless experience for patients. The companies and platforms that lead these partnerships, prioritizing data sharing and integration, will define the next era of clinical research.